Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 5;326(13):1299-1309.
doi: 10.1001/jama.2021.13844.

US Emergency Department Visits Attributed to Medication Harms, 2017-2019

Affiliations

US Emergency Department Visits Attributed to Medication Harms, 2017-2019

Daniel S Budnitz et al. JAMA. .

Abstract

Importance: Assessing the scope of acute medication harms to patients should include both therapeutic and nontherapeutic medication use.

Objective: To describe the characteristics of emergency department (ED) visits for acute harms from both therapeutic and nontherapeutic medication use in the US.

Design, setting, and participants: Active, nationally representative, public health surveillance based on patient visits to 60 EDs in the US participating in the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project from 2017 through 2019.

Exposures: Medications implicated in ED visits, with visits attributed to medication harms (adverse events) based on the clinicians' diagnoses and supporting data documented in the medical record.

Main outcomes and measures: Nationally weighted estimates of ED visits and subsequent hospitalizations for medication harms.

Results: Based on 96 925 cases (mean patient age, 49 years; 55% female), there were an estimated 6.1 (95% CI, 4.8-7.5) ED visits for medication harms per 1000 population annually and 38.6% (95% CI, 35.2%-41.9%) resulted in hospitalization. Population rates of ED visits for medication harms were higher for patients aged 65 years or older than for those younger than 65 years (12.1 vs 5.0 [95% CI, 7.4-16.8 vs 4.1-5.8] per 1000 population). Overall, an estimated 69.1% (95% CI, 63.6%-74.7%) of ED visits for medication harms involved therapeutic medication use, but among patients younger than 45 years, an estimated 52.5% (95% CI, 48.1%-56.8%) of visits for medication harms involved nontherapeutic use. The proportions of ED visits for medication harms involving therapeutic use were lowest for barbiturates (6.3%), benzodiazepines (11.1%), nonopioid analgesics (15.7%), and antihistamines (21.8%). By age group, the most frequent medication types and intents of use associated with ED visits for medication harms were therapeutic use of anticoagulants (4.5 [95% CI, 2.3-6.7] per 1000 population) and diabetes agents (1.8 [95% CI, 1.3-2.3] per 1000 population) for patients aged 65 years and older; therapeutic use of diabetes agents (0.8 [95% CI, 0.5-1.0] per 1000 population) for patients aged 45 to 64 years; nontherapeutic use of benzodiazepines (1.0 [95% CI, 0.7-1.3] per 1000 population) for patients aged 25 to 44 years; and unsupervised medication exposures (2.2 [95% CI, 1.8-2.7] per 1000 population) and therapeutic use of antibiotics (1.4 [95% CI, 1.0-1.8] per 1000 population) for children younger than 5 years.

Conclusions and relevance: According to data from 60 nationally representative US emergency departments, visits attributed to medication harms in 2017-2019 were frequent, with variation in products and intent of use by age.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Estimated Annual Emergency Department (ED) Visits for Medication Harms per 1000 Population, by Therapeutic vs Nontherapeutic Medication Use—US, 2017-2019
Estimates and 2-sided 95% CIs (error bars) were calculated from statistical weighting of 96 925 cases from 60 nationally representative hospitals participating in the National Electronic Injury Surveillance System–Cooperative Adverse Drug Event Surveillance Project for 2017-2019, Centers for Disease Control and Prevention. The population of each age group for 2017-2019 was calculated with intercensal estimates produced by the US Census Bureau. Patient age was missing for 13 cases (data not shown).
Figure 2.
Figure 2.. Estimated Annual Emergency Department (ED) Visits for Medication Harms per 1000 Population, by Age and Intent of Medication Use—US, 2017-2019
Estimates were calculated from statistical weighting of 96 925 cases from 60 nationally representative hospitals participating in the National Electronic Injury Surveillance System–Cooperative Adverse Drug Event Surveillance Project for 2017-2019, Centers for Disease Control and Prevention. The population of each age group for 2017-2019 was calculated with intercensal estimates produced by the US Census Bureau. The estimate of ED visits for abuse, misuse, or overdose without indication of intent for children younger than 5 years is based on fewer than 20 cases and is considered statistically unstable. Patient age was missing for 13 cases (data not shown).

References

    1. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140(10):795-801. - PubMed
    1. Bates DW, Slight SP. Medication errors: what is their impact? Mayo Clin Proc. 2014;89(8):1027-1029. doi:10.1016/j.mayocp.2014.06.014 - DOI - PubMed
    1. Hertz JA, Knight JR. Prescription drug misuse: a growing national problem. Adolesc Med Clin. 2006;17(3):751-769. - PubMed
    1. Stone DM, Holland KM, Bartholow B, et al. . Deciphering suicide and other manners of death associated with drug intoxication: a Centers for Disease Control and Prevention consultation meeting summary. Am J Public Health. 2017;107(8):1233-1239. doi:10.2105/AJPH.2017.303863 - DOI - PMC - PubMed
    1. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15):1858-1866. doi:10.1001/jama.296.15.1858 - DOI - PubMed

MeSH terms